Ligand Pharmaceuticals and Medtronic Cardiac and Vascular commit $70 Million in strategic capital to Orchestra BioMed. Details at a glance: 🫀Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement 🫀Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share 🫀Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers 📄 Read the full press release: https://lnkd.in/gQ2Sh58x #OrchestratingInnovation #MedTech #Financing #Partnerships
Orchestra BioMed
Biotechnology Research
A biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine.
About us
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Under these collaborations, Orchestra BioMed advances its promising therapeutic solutions through late-stage clinical research and regulatory approvals, while its collaborators focus on leveraging their commercial expertise and existing infrastructure to bring these product candidates to global markets quickly and efficiently. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com.
- Website
-
https://www.orchestrabiomed.com
External link for Orchestra BioMed
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Type
- Public Company
- Founded
- 2017
Employees at Orchestra BioMed
Updates
-
We asked our team: What’s your ultimate song of the summer? The result? A playlist that spans every genre and vibe; just like our dynamic ensemble. Hit play and get a glimpse of the beats that drive us. 🎧 https://lnkd.in/g9epEbm2 #SongsOfTheSummer #WorkplacePlaylist #SummerVibes
-
-
Our echocardiographic data analysis demonstrated the favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, covered in Diagnostic and Interventional Cardiology (DAIC) Magazine. Learn more about what this means for OBIO’s business model here: https://lnkd.in/gm9DQn4k #Cardiology #OrchestratingInnovation
-
#ICYMI: Watch a snippet from our CEO David Hochman's interview with Innovators' Jane King at the #NYSE. Watch the full interview to learn more about: ✅ How our partnership-enabled business model optimizes the development and commercialization of novel therapies ✅ Our investigational AVIM therapy and its potential to address the unmet medical need in hypertension management ✅ How we’re charging ahead to bring our pipeline of high impact solutions to market with world-class strategic partners Link here: https://lnkd.in/edkwADiK For disclaimers: http://bit.ly/4nHgE6t #OrchestratingInnovation #MedTech #Cardiology
-
Watch Dr. Avi Fischer, our Senior VP of Medical Affairs and Innovation, break down how AVIM therapy leverages existing pacemakers to lower #BloodPressure without added procedures. 💡 #OrchestratingInnovation
-
How do we improve opportunities for patients confronting life-threatening cardiovascular conditions? Dr. David Kandzari describes how new innovations that are enhancing well-established technologies like #pacemakers to balloon #angioplasty are providing new therapeutic options for patients. #OrchestratingInnovation
-
Our CEO, David Hochman, recently visited the #NYSE for an interview with Innovators Weekly’s Jane King to discuss Orchestra BioMed’s unique approach to advancing high-impact therapies for underserved patients with two of the world’s most pressing health challenges: hypertension and coronary artery disease. We’re proud to bring our story to such an iconic stage. Watch the full interview here: https://lnkd.in/edkwADiK For Disclaimers: http://bit.ly/4nHgE6t #OrchestratingInnovation #Cardiology #MedTech
-
-
As the global population climbs past 8 billion, the burdens of age-related #cardiovascular conditions continue to grow. This #WorldPopulationDay, we’re reminded that the health of billions depends on the progress of those working to improve the status quo. At Orchestra BioMed, we’re focused on enabling new solutions for this massive unmet need. #MedTech #HypertensiveHeartDisease #OrchestratingInnovation
-
Every advancement in #Medtech starts with people who think outside the box, push boundaries, and drive progress. Meet Michelle Toledo, Quality Manager, New Product Development & Clinical. Her work helps drive our commitment to accelerating life-changing therapies for patients. Join us in celebrating their impact! #OrchestratingInnovation #InnovationInHealthcare
-
-
Medication adherence is one of the most significant challenges in today’s standard of care. Our investigational AVIM therapy has the potential to offer a more patient-friendly approach for those who struggle with medication adherence. Read more in Medscape’s article: https://lnkd.in/e4yrKd-q For disclaimers, please visit: https://lnkd.in/gfJiBn_j #OrchestratingInnovation #MedTech
-